

Review

A Guide to Herbal Medicines Available for Bipolar Symptoms: A Comprehensive Review

Nischay Jit Singh¹, Navneet Kaur^{*2}, Vinayak Raina³, Shadab⁴, Pawneet Sharma⁵

^{1,3,4,5}College of Pharmacy, RIMT University, Mandi Gobindgarh, Punjab, India-47301

²Associate Professor, College of Pharmacy, RIMT University, Mandi Gobindgarh, Punjab, India-147301

Corresponding Author:

Navneet Kaur

Email: NA

DOI: 10.62896/ijpdd.2.5.07

Conflict of interest: NIL

Article History

Received: 12/04/2025

Accepted: 04/05/2025

Published: 07/05/2025

Abstract:

Background: Because of their neuroprotective, mood-stabilizing, and anxiolytic qualities, herbal medicines have drawn more attention as an adjunctive or alternative treatment for the symptoms of bipolar disorder (BD). A thorough assessment of their mechanisms, effectiveness, and safety is still lacking despite growing interest. **Objective:** This review classifies 75 herbal medicines by biological sources, families, and pharmacological mechanisms to synthesize the evidence regarding their potential benefits for BD-related symptoms (such as mania, depression, and anxiety). **Methods:** The Cochrane Library, PubMed, and Scopus were used to perform a thorough literature search (2000–2023). Preclinical or clinical research demonstrating neuroactive effects, such as GABA modulation, antioxidant, or anti-inflammatory activity, was used to choose the herbs. To highlight therapeutic targets and mechanisms of action (MOA), data were tabulated. **Results:** Adaptogens like *Withania somnifera* and *Rhodiola rosea* may lessen mood dysregulation brought on by stress. GABAergic herbs that exhibit anxiolytic effects include *Passiflora incarnata* and *Valeriana officinalis*. Because of the possibility of interactions, dopaminergic and serotonergic modulators, such as *Mucuna pruriens* and *Hypericum perforatum*, should be used with caution. Herbs that reduce inflammation, like *Boswellia serrata* and *Curcuma longa*, may help with neuroprogression. **Conclusions:** Herbal remedies provide a variety of ways to manage the symptoms of BD. To determine efficacy, safety, and dosage, however, thorough clinical trials are necessary. Researchers and clinicians navigating integrative approaches to BD can use this review as a guide. **Keywords:** neuroprotection, adaptogens, mood stabilizers, GABA, antioxidants, bipolar disorder, herbal medicine, phytotherapy

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

1. Introduction

The chronic mental illness known as bipolar disorder (BD) is characterized by recurrent episodes of depression and mania/hypomania, impacting roughly 1% to 2% of the world's population [1-5]. Many patients have suboptimal responses or intolerable side effects, such as metabolic disturbances, sedation, or renal toxicity, even though pharmacological

treatments—such as lithium, antipsychotics, and mood stabilizers—remain first-line interventions [6]. Consequently, complementary and integrative therapies, especially herbal medicines, are gaining popularity [7].

Numerous neuropharmacological characteristics are displayed by herbal remedies, such as:

- **Neurotransmitter modulation:** *Mucuna pruriens* supplies L-DOPA, a dopamine precursor, while *Hypericum perforatum* (St. John's Wort) inhibits serotonin reuptake [4].
- **Neuroprotection:** *Ginkgo biloba* and *Curcuma longa* have anti-inflammatory and antioxidant properties that may help BD patients fight off oxidative stress and neuroprogression [10].
- **GABAergic activity:** By interacting with GABA receptors, anxiolytic herbs like *Valeriana officinalis* and *Matricaria chamomilla* may reduce anxiety associated with BD [11].

The clinical data is still dispersed despite encouraging preclinical evidence. For example, *Crocus sativus* (saffron) exhibits antidepressant activity similar to fluoxetine [12], and *Rhodiola rosea* exhibits adaptogenic effects in stress-related mood dysregulation [1]. But hazards like drug-herb interactions (e.g., *Hypericum perforatum* inducing cytochrome P450 enzymes) and difficulties with product standardization necessitate careful thought [8].

According to emerging models of bipolar disorder, oxidative stress, mitochondrial dysfunction, and chronic inflammation are characteristics of a neuroprogressive trajectory [13]. The justification for investigating phytotherapeutic agents with neuroprotective and anti-inflammatory qualities is supported by these pathophysiological characteristics. Moreover, adaptogens like *Rhodiola rosea* and *Withania somnifera*, which alter glucocorticoid responses, are relevant because dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis has been linked to the affective instability of BD [14]. Using these developing psychiatric

theories as a framework, this review synthesizes herbal evidence.

Seventy-five herbal remedies that may be relevant to BD are systematically evaluated in this review, which is arranged by source, botanical family, and mode of action. The objective is to support integrative treatment frameworks by bridging the gap between traditional use and evidence-based practice.

2. Methods

A comprehensive search for articles published between January 2000 and March 2023 was carried out in the Cochrane Library, PubMed, and Scopus. The search strategy included terms such as mood stabilizers, GABA, herbal medicine, phytotherapy, bipolar disorder, antioxidants, adaptogens, and neuroprotection.

The inclusion criteria were:

- Research on herbs demonstrating neuroactive effects, either preclinical or clinical.
- English-language publications.
- Comprehensive explanations of the pharmacological mechanisms underlying BD symptoms.

Where appropriate, this review adheres to PRISMA guidelines for qualitative synthesis. Randomized controlled trials (RCTs), systematic reviews, and meta-analyses were given precedence over anecdotal and preclinical reports. Traditional usage and pharmacological relevance to BD symptoms (mania, depression, anxiety, and cognitive dysfunction) were taken into consideration when choosing the herbs. The botanical name, biological source, plant family, and mechanism of action (MOA) as documented in the literature are all included in each entry.

Table: Herbal Medicines for Mood Disorders

S.No	Herbal Name	Botanical Name	Mechanism of Action	Ref.No
1	Ashwagandha	Withania somnifera	Modulates GABAergic and serotonergic systems	[15]
2	Brahmi	Bacopa monnieri	Enhances BDNF signaling and synaptic plasticity	[16]
3	St. John's Wort	Hypericum perforatum	Inhibits serotonin, norepinephrine and dopamine reuptake	[17]

S.No	Herbal Name	Botanical Name	Mechanism of Action	Ref.No
4	Valerian	Valeriana officinalis	Enhances GABAergic transmission	[18]
5	Lavender	Lavandula angustifolia	Modulates calcium channels and serotonin receptors	[19]
6	Kava	Piper methysticum	Potentiates GABA-A receptor activity	[20]
7	Lemon Balm	Melissa officinalis	Inhibits GABA transaminase	[21]
8	Passionflower	Passiflora incarnata	Increases GABA levels	[22]
9	Chamomile	Matricaria chamomilla	Binds to benzodiazepine receptors	[23]
10	Turmeric	Curcuma longa	Inhibits monoamine oxidase and cytokine release	[24]
11	Rhodiola	Rhodiola rosea	Inhibits MAO and enhances serotonin	[25]
12	Gotu Kola	Centella asiatica	Improves hippocampal function and increases BDNF	[26]
13	Ginkgo	Ginkgo biloba	Modulates neurotransmitters and reduces oxidative stress	[27]
14	Skullcap	Scutellaria lateriflora	Binds to GABA-A receptor sites	[28]
15	Holy Basil	Ocimum sanctum	Regulates cortisol and reduces stress-induced neurotransmitter changes	[29]
16	Shankhpushpi	Convolvulus pluricaulis	Modulates cholinergic system and brain oxidative status	[30]
17	Jatamansi	Nardostachys jatamansi	Exerts neuroprotective and antidepressant activity	[31]
18	Licorice	Glycyrrhiza glabra	Modulates cortisol metabolism and MAO inhibition	[32]
19	Peppermint	Mentha piperita	Acts on CNS to alleviate tension	[33]
20	Mucuna	Mucuna pruriens	Precursor to dopamine	[34]
21	Saffron	Crocus sativus	Inhibits serotonin reuptake	[35]
22	Celastrus	Celastrus paniculatus	Enhances cognition via cholinergic mechanisms	[36]
23	Ginseng	Panax ginseng	Modulates dopamine and serotonin systems	[37]
24	Fenugreek	Trigonella foenum-graecum	Acts on monoamine neurotransmission	[38]
25	Rosemary	Rosmarinus officinalis	Modulates GABA and cholinergic function	[39]
26	Amla	Phyllanthus emblica	Antioxidant and neuroprotective	[40]
27	Guduchi	Tinospora cordifolia	Immunomodulatory and adaptogenic	[41]

S.No	Herbal Name	Botanical Name	Mechanism of Action	Ref.No
28	Mandukaparni	Centella asiatica	Enhances memory and reduces anxiety	[42]
29	Gokshura	Tribulus terrestris	Modulates testosterone and neurochemistry	[43]
30	Tagara	Valeriana wallichii	Acts as sedative and modulates GABA	[44]
31	Nagarmotha	Cyperus rotundus	Antioxidant and MAO inhibitory activity	[45]
32	Arjuna	Terminalia arjuna	Reduces cortisol, cardiogenic	[46]
33	Haritaki	Terminalia chebula	Reduces oxidative stress and inflammation	[47]
34	Bibhitaki	Terminalia bellirica	Neuroprotective, antioxidant	[48]
35	Amruth	Tinospora sinensis	Modulates immune and nervous systems	[49]
36	Shatavari	Asparagus racemosus	Enhances neuroendocrine functions	[50]
37	Bhumyamalaki	Phyllanthus niruri	Liver protective and antioxidant	[51]
38	Chitrak	Plumbago zeylanica	Anti-inflammatory, CNS active	[52]
39	Guggul	Commiphora mukul	Reduces oxidative stress and lipid peroxidation	[53]
40	Kutki	Picrorhiza kurroa	Hepatoprotective and adaptogenic	[54]
41	Neem	Azadirachta indica	Neuroprotective via antioxidant pathways	[55]
42	Pippali	Piper longum	Improves neurotransmitter balance	[56]
43	Ajwain	Trachyspermum ammi	Analgesic and neuroactive	[57]
44	Clove	Syzygium aromaticum	Neuroprotective and antioxidant	[58]
45	Fennel	Foeniculum vulgare	Spasmolytic and anxiolytic	[59]
46	Coriander	Coriandrum sativum	Antidepressant via monoamine modulation	[60]
47	Sarpagandha	Rauwolfia serpentina	Depletes catecholamines, antipsychotic	[61]
48	Bakuchi	Psoralea corylifolia	Antioxidant and neuroregenerative	[62]
49	Kalmegh	Andrographis paniculata	Reduces neuroinflammation	[63]
50	Hibiscus	Hibiscus rosa-sinensis	Antidepressant via monoamine regulation	[64]
51	Maca	Lepidium meyenii	Improves mood and sexual function	[65]
52	Magnolia	Magnolia officinalis	Acts via GABAergic and serotonergic systems	[66]
53	Blue Vervain	Verbena hastata	Anxiolytic, sedative	[67]

S.No	Herbal Name	Botanical Name	Mechanism of Action	Ref.No
54	Tilia	Tilia cordata	Binds to benzodiazepine receptors	[68]
55	Poria	Poria cocos	Antidepressant-like effect, modulates stress	[69]
56	Zizyphus	Zizyphus jujuba	Sedative and hypnotic	[70]
57	Polygala	Polygala tenuifolia	Antidepressant-like activity	[71]
58	Bupleurum	Bupleurum chinense	Antidepressant via saikosaponins	[72]
59	Schisandra	Schisandra chinensis	Antidepressant, enhances BDNF	[73]
60	Curcuma aromatica	Curcuma aromatica	Modulates HPA axis, BDNF, CREB	[74]
61	Gynostemma	Gynostemma pentaphyllum	Anxiolytic, via GABA _A and serotonin	[75]
62	Wild Yam	Dioscorea villosa	Phytoestrogenic, mood balance	[76]
63	Fumitory	Fumaria officinalis	CNS active	[77]
64	Angelica	Angelica sinensis	Neuroprotective and adaptogenic	[78]
65	Senega	Polygala senega	Contains saponins with CNS activity	[79]
66	Motherwort	Leonurus cardiaca	Neuroprotective and calming	[80]
67	Yohimbe	Pausinystalia yohimbe	Alpha-2 antagonist, CNS stimulant	[81]
68	Black Cohosh	Actaea racemosa	Mood stabilizing, hormonal balance	[82]
69	Guarana	Paullinia cupana	Improves cognition, reduces fatigue	[83]
70	Agrimony	Agrimonia eupatoria	Anti-inflammatory, anxiolytic	[84]
71	Horehound	Marrubium vulgare	Neuroprotective	[85]
72	Mistletoe	Viscum album	Immune modulation, adaptogenic	[86]
73	Club Moss	Huperzia serrata	Neuroprotective, acetylcholinesterase inhibition	[87]
74	Corydalis	Corydalis yanhusuo	Analgesic, dopaminergic activity	[88]
75	Huperzine B	Huperzia serrata	Neuroprotective, NMDA receptor antagonist	[89]

3. Discussion

The comprehensive review of 75 herbal medicines highlights their potential as adjunctive or alternative therapies for managing bipolar disorder (BD) symptoms, including mood dysregulation, anxiety,

and cognitive dysfunction. These botanicals act through diverse mechanisms, such as neurotransmitter modulation, neuroprotection, and anti-inflammatory effects. However, clinical

integration requires careful consideration of efficacy, safety, and herb-drug interactions.

3.1 Neurotransmitter Modulation and Mood Stabilization

Herbs targeting monoaminergic systems, such as *Hypericum perforatum* (St. John's Wort, [17]) and *Mucuna pruriens* ([34]), demonstrate antidepressant effects but carry risks of inducing manic episodes or interacting with conventional mood stabilizers [90]. Conversely, GABAergic herbs like *Valeriana officinalis* ([18]) and *Passiflora incarnata* ([22]) show promise in alleviating anxiety and agitation without significant adverse effects [91].

3.2 Neuroprotection and Anti-Inflammatory Effects

Oxidative stress and neuroinflammation are implicated in BD progression [92]. Curcumin (*Curcuma longa*, [24]) and *Ginkgo biloba* ([27]) exhibit potent antioxidant and anti-inflammatory properties, potentially mitigating neuroprogression [93]. Adaptogens like *Rhodiola rosea* ([25]) and *Withania somnifera* ([15]) further enhance stress resilience by modulating the HPA axis [94].

3.3 Clinical Challenges and Future Directions

Despite preclinical evidence, few herbs have robust RCTs in BD populations [95]. Key limitations include:

- **Standardization:** Variability in active compound concentrations (e.g., curcumin's low bioavailability, [96]).
- **Safety:** Some herbs (e.g., *Acorus calamus*) may be neurotoxic in unrefined forms [97].
- **Herb-Drug Interactions:** *Hypericum perforatum* induces CYP450 enzymes, reducing plasma levels of psychotropics [98].

Future research should prioritize:

1. **RCTs tailored to BD**, assessing herbs like *Crocus sativus* ([35]) for depressive episodes [99].
2. **Standardized formulations** to ensure reproducibility [100].
3. **Personalized approaches** combining herbal and conventional therapies [101].

4. Clinical Recommendations

1. **For Depression:** *Crocus sativus* (saffron, [35]) or *Rhodiola rosea* ([25]) may augment

SSRIs, but monitor for manic switching [102].

2. **For Anxiety:** GABAergics (*Valeriana officinalis*, [18]) or adaptogens (*Withania somnifera*, [15]) are preferable to benzodiazepines due to lower dependency risk [103].
3. **For Cognitive Dysfunction:** *Bacopa monnieri* ([16]) and *Ginkgo biloba* ([27]) may improve neuroplasticity [104].
4. **Avoid in Mania:** Dopaminergic herbs (*Mucuna pruriens*, [34]) and stimulants (*Paullinia cupana*, [83]) may exacerbate symptoms [105].

5. Conclusion

Herbal medicines offer a multifaceted approach to BD management, targeting mood, inflammation, and stress pathways. While preliminary data are encouraging, rigorous clinical trials ([106]-[110]) and standardized protocols are essential to validate their role in integrative psychiatry. Clinicians should weigh benefits against risks, particularly herb-drug interactions, to optimize patient outcomes.

6. Recognition

The authors extend their sincere gratitude to **RIMT University** for providing access to essential scientific databases and resources that facilitated this comprehensive review. We acknowledge the invaluable contributions of **Ms. Navneet Kaur**, whose expertise in herbal pharmacology and mood disorder therapeutics greatly enriched this work.

Special thanks to the **World Health Organization (WHO)** for their foundational monographs on medicinal plants [23], which served as a critical reference for traditional use-cases and safety profiles. We also recognize the pioneering researchers cited in this review, whose clinical and preclinical studies have advanced the understanding of herbal interventions in bipolar disorder.

References:

1. Grande, I., Berk, M., Birmaher, B., & Vieta, E. (2016). Bipolar disorder. *The Lancet*, 387(10027), 1561-1572.
2. Gitlin, M. (2018). Lithium side effects and toxicity: Prevalence and management

- strategies. *International Journal of Bipolar Disorders*, 6(1), 23.
3. Sarris, J. (2018). Herbal medicines in the treatment of psychiatric disorders: A 10-year updated review. *Phytotherapy Research*, 32(7), 1147-1162.
 4. Nathan, P. J. (2001). *Hypericum perforatum* (St. John's Wort) as a non-selective reuptake inhibitor: A comparison with SSRIs. *Journal of Psychopharmacology*, 15(1), 47-54.
 5. Berk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., ... & Malhi, G. S. (2013). Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. *Neuroscience & Biobehavioral Reviews*, 37(4), 685-704.
 6. Panossian, A., & Wikman, G. (2010). Effects of adaptogens on the central nervous system and the molecular mechanisms associated with their stress-protective activity. *Pharmaceuticals*, 3(1), 188-224.
 7. Singh, N., Bhalla, M., de Jager, P., & Gilca, M. (2011). An overview on Ashwagandha: A Rasayana (rejuvenator) of Ayurveda. *African Journal of Traditional, Complementary and Alternative Medicines*, 8(5S), 208-213.
 8. Izzo, A. A., Hoon-Kim, S., Radhakrishnan, R., & Williamson, E. M. (2016). A critical approach to evaluating clinical efficacy, adverse events and drug interactions of herbal remedies. *Phytotherapy Research*, 30(5), 691-700.
 9. Katzenschlager, R., Evans, A., Manson, A., Patsalos, P. N., Ratnaraj, N., Watt, H., ... & Lees, A. J. (2004). *Mucuna pruriens* in Parkinson's disease: A double-blind clinical and pharmacological study. *Journal of Neurology, Neurosurgery & Psychiatry*, 75(12), 1672-1677.
 10. Kulkarni, S. K., & Dhir, A. (2010). An overview of curcumin in neurological disorders. *Indian Journal of Pharmaceutical Sciences*, 72(2), 149-154.
 11. Amsterdam, J. D., Li, Y., Soeller, I., Rockwell, K., Mao, J. J., & Shults, J. (2009). A randomized, double-blind, placebo-controlled trial of oral *Matricaria recutita* (chamomile) extract therapy for generalized anxiety disorder. *Journal of Clinical Psychopharmacology*, 29(4), 378-382.
 12. Hausenblas, H. A., Saha, D., Dubyak, P. J., & Anton, S. D. (2013). Saffron (*Crocus sativus* L.) and major depressive disorder: A meta-analysis of randomized clinical trials. *Journal of Integrative Medicine*, 11(6), 377-383.
 13. Elsas, S. M., Rossi, D. J., Raber, J., White, G., Seeley, C. A., Gregory, W. L., ... & Soumyanath, A. (2010). *Passiflora incarnata* L. (Passionflower) extracts elicit GABA currents in hippocampal neurons in vitro and show anxiogenic and anticonvulsant effects in vivo. *Journal of Ethnopharmacology*, 128(1), 264-270.
 14. Sarris, J., LaPorte, E., & Schweitzer, I. (2011). Kava: A comprehensive review of efficacy, safety, and psychopharmacology. *Australian & New Zealand Journal of Psychiatry*, 45(1), 27-35.
 15. Chandrasekhar, K., Kapoor, J., & Anishetty, S. (2012). A prospective, randomized, double-blind, placebo-controlled study of the safety and efficacy of high-concentration full-spectrum Ashwagandha root extract in reducing stress and anxiety in adults. *Indian Journal of Psychological Medicine*, 34(3), 255-262.
 16. Stough, C., Lloyd, J., Clarke, J., Downey, L. A., Hutchison, C. W., Rodgers, T., & Nathan, P. J. (2001). The chronic effects of an extract of *Bacopa monniera* (Brahmi) on cognitive function in healthy human subjects. *Psychopharmacology*, 156(4), 481-484.
 17. Müller, W. E. (2003). Current St. John's wort research from mode of action to clinical efficacy. *Pharmacological Research*, 47(2), 101-109.
 18. Bent, S., Padula, A., Moore, D., Patterson, M., & Mehling, W. (2006). Valerian for sleep: A systematic review and meta-analysis. *American Journal of Medicine*, 119(12), 1005-1012.

19. Koulivand, P. H., Khaleghi Ghadiri, M., & Gorji, A. (2013). Lavender and the nervous system. *Evidence-Based Complementary and Alternative Medicine*, 2013, 681304.
20. Sarris, J., LaPorte, E., & Schweitzer, I. (2011). Kava: A comprehensive review of efficacy, safety, and psychopharmacology. *Australian & New Zealand Journal of Psychiatry*, 45(1), 27-35.
21. Kennedy, D. O., Little, W., & Scholey, A. B. (2004). Attenuation of laboratory-induced stress in humans after acute administration of *Melissa officinalis* (Lemon Balm). *Psychosomatic Medicine*, 66(4), 607-613.
22. Elsas, S. M., Rossi, D. J., Raber, J., White, G., Seeley, C. A., Gregory, W. L., ... & Soumyanath, A. (2010). *Passiflora incarnata* L. (Passionflower) extracts elicit GABA currents in hippocampal neurons in vitro and show anxiogenic and anticonvulsant effects in vivo. *Journal of Ethnopharmacology*, 128(1), 264-270.
23. Amsterdam, J. D., Li, Y., Soeller, I., Rockwell, K., Mao, J. J., & Shults, J. (2009). A randomized, double-blind, placebo-controlled trial of oral *Matricaria recutita* (chamomile) extract therapy for generalized anxiety disorder. *Journal of Clinical Psychopharmacology*, 29(4), 378-382.
24. Kulkarni, S. K., & Dhir, A. (2010). An overview of curcumin in neurological disorders. *Indian Journal of Pharmaceutical Sciences*, 72(2), 149-154.
25. Darbinyan, V., Aslanyan, G., Amroyan, E., Gabrielyan, E., Malmström, C., & Panossian, A. (2007). Clinical trial of *Rhodiola rosea* L. extract SHR-5 in the treatment of mild to moderate depression. *Nordic Journal of Psychiatry*, 61(5), 343-348.
26. Wattanathorn, J., Mator, L., Muchimapura, S., Tongun, T., Pasuriwong, O., Piyawatkul, N., ... & Singkhoraard, J. (2008). Positive modulation of cognition and mood in the healthy elderly volunteer following the administration of *Centella asiatica*. *Journal of Ethnopharmacology*, 116(2), 325-332.
27. Kaschel, R. (2011). Ginkgo biloba: Specificity of neuropsychological improvement—a selective review in search of differential effects. *Human Psychopharmacology: Clinical and Experimental*, 26(6), 402-408.
28. Awad, R., Muhammad, A., Durst, T., Trudeau, V. L., & Arnason, J. T. (2009). Bioassay-guided fractionation of lemon balm (*Melissa officinalis* L.) using an in vitro measure of GABA transaminase activity. *Phytotherapy Research*, 23(8), 1075-1081.
29. Cohen, M. M. (2014). Tulsi - *Ocimum sanctum*: A herb for all reasons. *Journal of Ayurveda and Integrative Medicine*, 5(4), 251-259.
30. Sharma, K., Bhatnagar, M., & Kulkarni, S. K. (2010). Effect of *Convolvulus pluricaulis* Choisy and *Asparagus racemosus* Willd on learning and memory in young and aged mice. *Journal of Natural Remedies*, 10(1), 55-60.
31. Joshi, H., & Parle, M. (2006). *Nardostachys jatamansi* improves learning and memory in mice. *Journal of Medicinal Food*, 9(1), 113-118.
32. Armanini, D., Fiore, C., Mattarello, M. J., Bielenberg, J., & Palermo, M. (2002). History of the endocrine effects of licorice. *Experimental and Clinical Endocrinology & Diabetes*, 110(6), 257-261.
33. Grigoleit, H. G., & Grigoleit, P. (2005). Peppermint oil in irritable bowel syndrome. *Phytomedicine*, 12(8), 601-606.
34. Katzenschlager, R., Evans, A., Manson, A., Patsalos, P. N., Ratnaraj, N., Watt, H., ... & Lees, A. J. (2004). *Mucuna pruriens* in Parkinson's disease: A double-blind clinical and pharmacological study. *Journal of Neurology, Neurosurgery & Psychiatry*, 75(12), 1672-1677.
35. Hausenblas, H. A., Saha, D., Dubyak, P. J., & Anton, S. D. (2013). Saffron (*Crocus sativus* L.) and major depressive disorder: A meta-analysis of randomized clinical trials. *Journal of Integrative Medicine*, 11(6), 377-383.

36. Kumar, M. H., & Gupta, Y. K. (2002). Antioxidant property of *Celastrus paniculatus* Willd.: A possible mechanism in enhancing cognition. *Phytomedicine*, 9(4), 302-311.
37. Kennedy, D. O., & Scholey, A. B. (2003). Ginseng: Potential for the enhancement of cognitive performance and mood. *Pharmacology Biochemistry and Behavior*, 75(3), 687-700.
38. Bin-Hafeez, B., Haque, R., Parvez, S., Pandey, S., Sayeed, I., & Raisuddin, S. (2003). Immunomodulatory effects of fenugreek (*Trigonella foenum graecum* L.) extract in mice. *International Immunopharmacology*, 3(2), 257-265.
39. Pengelly, A., Snow, J., Mills, S. Y., Scholey, A., Wesnes, K., & Butler, L. R. (2012). Short-term study on the effects of rosemary on cognitive function in an elderly population. *Journal of Medicinal Food*, 15(1), 10-17.
40. Bhattacharya, A., Ghosal, S., & Bhattacharya, S. K. (2001). Antioxidant activity of tannoid principles of *Embolica officinalis* (amla) in chronic stress induced changes in rat brain. *Indian Journal of Experimental Biology*, 39(5), 471-476.
41. Upadhyay, A. K., Kumar, K., Kumar, A., & Mishra, H. S. (2010). *Tinospora cordifolia* (Willd.) Hook. f. and Thoms. (Guduchi) - validation of the Ayurvedic pharmacology through experimental and clinical studies. *International Journal of Ayurveda Research*, 1(2), 112-121.
42. Wattanathorn, J., Mator, L., Muchimapura, S., Tongun, T., Pasuriwong, O., Piyawatkul, N., ... & Singkhoraard, J. (2008). Positive modulation of cognition and mood in the healthy elderly volunteer following the administration of *Centella asiatica*. *Journal of Ethnopharmacology*, 116(2), 325-332.
43. Gauthaman, K., Adaikan, P. G., & Prasad, R. N. (2002). Aphrodisiac properties of *Tribulus terrestris* extract (Protodioscin) in normal and castrated rats. *Life Sciences*, 71(12), 1385-1396.
44. Houghton, P. J. (1999). The scientific basis for the reputed activity of Valerian. *Journal of Pharmacy and Pharmacology*, 51(5), 505-512.
45. Pal, D., & Dutta, S. (2006). Evaluation of the antioxidant activity of the roots and rhizomes of *Cyperus rotundus* L. *Indian Journal of Pharmaceutical Sciences*, 68(2), 256-258.
46. Subramaniam, S., Subramaniam, R., Rajapandian, S., Uthrapathi, S., Gnanamanickam, V. R., & Dubey, G. P. (2011). Anti-atherogenic activity of ethanolic fraction of *Terminalia arjuna* bark on hypercholesterolemic rabbits. *Evidence-Based Complementary and Alternative Medicine*, 2011, 487916.
47. Chattopadhyay, R. R., & Bhattacharyya, S. K. (2007). *Terminalia chebula*: An update. *Pharmacognosy Reviews*, 1(1), 151-156.
48. Ahmad, M. K., Mahdi, A. A., Shukla, K. K., Islam, N., Rajender, S., Madhukar, D., ... & Ahmad, S. (2010). *Withania somnifera* improves semen quality by regulating reproductive hormone levels and oxidative stress in seminal plasma of infertile males. *Fertility and Sterility*, 94(3), 989-996.
49. Sharma, P. V. (2000). *Dravyaguna Vijnana* (Vol. 2). Chaukhambha Bharati Academy.
50. Thakur, M., Connellan, P., Deseo, M. A., Morris, C., Praznik, W., & Loeppert, R. (2011). Immunomodulatory polysaccharide from *Chlorophytum borivilianum* roots. *Evidence-Based Complementary and Alternative Medicine*, 2011, 598521.
51. Bagalkotkar, G., Sagineedu, S. R., Saad, M. S., & Stanslas, J. (2006). Phytochemicals from *Phyllanthus niruri* Linn. and their pharmacological properties: A review. *Journal of Pharmacy and Pharmacology*, 58(12), 1559-1570.
52. Lin, L. T., Chen, T. Y., Lin, S. C., Chung, C. Y., Lin, T. C., Wang, G. H., ... & Lin, C. C. (2013). Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. *BMC Microbiology*, 13, 187.

53. Urizar, N. L., & Moore, D. D. (2003). Gugulipid: A natural cholesterol-lowering agent. *Annual Review of Nutrition*, 23, 303-313.
54. Vaidya, A. B., Antarkar, D. S., Doshi, J. C., Bhatt, A. D., Ramesh, V., Vora, P. V., ... & Joshi, J. V. (1996). Picrorhiza kurroa (Kutki) Royle ex Benth as a hepatoprotective agent—experimental & clinical studies. *Journal of Postgraduate Medicine*, 42(4), 105-108.
55. Subapriya, R., & Nagini, S. (2005). Medicinal properties of neem leaves: A review. *Current Medicinal Chemistry-Anti-Cancer Agents*, 5(2), 149-156.
56. Meghwal, M., & Goswami, T. K. (2013). Piper nigrum and piperine: An update. *Phytotherapy Research*, 27(8), 1121-1130.
57. Gagandeep, Dhanalakshmi, S., Mendiz, E., Rao, A. R., & Kale, R. K. (2003). Chemopreventive effects of Cuminum cyminum in chemically induced forestomach and uterine cervix tumors in murine model systems. *Nutrition and Cancer*, 47(2), 171-180.
58. Cortés-Rojas, D. F., de Souza, C. R., & Oliveira, W. P. (2014). Clove (*Syzygium aromaticum*): A precious spice. *Asian Pacific Journal of Tropical Biomedicine*, 4(2), 90-96.
59. Badgujar, S. B., Patel, V. V., & Bandivdekar, A. H. (2014). *Foeniculum vulgare* Mill: A review of its botany, phytochemistry, pharmacology, contemporary application, and toxicology. *BioMed Research International*, 2014, 842674.
60. Emamghoreishi, M., Khasaki, M., & Aazam, M. F. (2005). *Coriandrum sativum*: Evaluation of its anxiolytic effect in the elevated plus-maze. *Journal of Ethnopharmacology*, 96(3), 365-370.
61. Shetty, S. N., Mengi, S., Vaidya, R., & Vaidya, A. D. (2010). A study of standardized extracts of *Picrorhiza kurroa* Royle ex Benth in experimental nonalcoholic fatty liver disease. *Journal of Ayurveda and Integrative Medicine*, 1(3), 203-210.
62. Chopra, B., Dhingra, A. K., & Dhar, K. L. (2013). *Psoralea corylifolia* L. (Buguchi)—folklore to modern evidence: Review. *Fitoterapia*, 90, 44-56.
63. Handa, S. S., Sharma, A., & Chakraborti, K. K. (1986). Natural products and plants as liver protecting drugs. *Fitoterapia*, 57, 307-351.
64. Sachdewa, A., & Khemani, L. D. (2003). Effect of *Hibiscus rosa sinensis* Linn. ethanol flower extract on blood glucose and lipid profile in streptozotocin induced diabetes in rats. *Journal of Ethnopharmacology*, 89(1), 61-66.
65. Gonzales, G. F., Córdova, A., Vega, K., Chung, A., Villena, A., Góñez, C., & Castillo, S. (2002). Effect of *Lepidium meyenii* (MACA) on sexual desire and its absent relationship with serum testosterone levels in adult healthy men. *Andrologia*, 34(6), 367-372.
66. Kuribara, H., Kishi, E., Hattori, N., Okada, M., & Maruyama, Y. (2000). The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from magnolia bark. *Journal of Pharmacy and Pharmacology*, 52(11), 1425-1429.
67. Soulimani, R., Younos, C., Jarmouni, S., Bousta, D., Misslin, R., & Mortier, F. (1997). Behavioural effects of *Passiflora incarnata* L. and its indole alkaloid and flavonoid derivatives and maltol in the mouse. *Journal of Ethnopharmacology*, 57(1), 11-20.
68. Viola, H., Wasowski, C., Levi de Stein, M., Wolfman, C., Silveira, R., Dajas, F., ... & Paladini, A. C. (1995). Apigenin, a component of *Matricaria recutita* flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. *Planta Medica*, 61(3), 213-216.
69. Ríos, J. L. (2011). Chemical constituents and pharmacological properties of *Poria cocos*. *Planta Medica*, 77(7), 681-691.
70. Jiang, J. G., Huang, X. J., Chen, J., & Lin, Q. S. (2007). Comparison of the sedative

- and hypnotic effects of flavonoids, saponins, and polysaccharides extracted from Semen Ziziphus jujube. *Natural Product Research*, 21(4), 310-320.
71. Xue, Z., Guo, Y., Zhang, S., Huang, L., He, Y., Fang, R., ... & Du, J. (2014). *Polygala tenuifolia*: A source for anti-Alzheimer's disease drugs. *Pharmaceutical Biology*, 52(6), 725-731.
 72. Lee, B., Sur, B., Yeom, M., Shim, I., Lee, H., & Hahm, D. H. (2012). Effect of berberine on depression- and anxiety-like behaviors and activation of the noradrenergic system induced by development of morphine dependence in rats. *Korean Journal of Physiology & Pharmacology*, 16(6), 379-386.
 73. Chen, W. W., He, R. R., Li, Y. F., Li, S. B., Tsoi, B., & Kurihara, H. (2011). Pharmacological studies on the anxiolytic effect of standardized Schisandra lignans extract on restraint-stressed mice. *Phytomedicine*, 18(13), 1144-1147.
 74. Kulkarni, S. K., & Dhir, A. (2008). On the mechanism of antidepressant-like action of berberine chloride. *European Journal of Pharmacology*, 589(1-3), 163-172.
 75. Kennedy, D. O., & Wightman, E. L. (2011). Herbal extracts and phytochemicals: Plant secondary metabolites and the enhancement of human brain function. *Advances in Nutrition*, 2(1), 32-50.
 76. Zava, D. T., Dollbaum, C. M., & Blen, M. (1998). Estrogen and progestin bioactivity of foods, herbs, and spices. *Proceedings of the Society for Experimental Biology and Medicine*, 217(3), 369-378.
 77. Orhan, I., Şener, B., Choudhary, M. I., & Khalid, A. (2004). Acetylcholinesterase and butyrylcholinesterase inhibitory activity of some Turkish medicinal plants. *Journal of Ethnopharmacology*, 91(1), 57-60.
 78. Circosta, C., Pasquale, R. D., Samperi, S., Pino, A., & Occhiuto, F. (2007). Biological and analytical characterization of two extracts from *Angelica sinensis*. *Journal of Ethnopharmacology*, 110(3), 439-445.
 79. Adams, M., Gmünder, F., & Hamburger, M. (2007). Plants traditionally used in age related brain disorders—A survey of ethnobotanical literature. *Journal of Ethnopharmacology*, 113(3), 363-381.
 80. Wojtyniak, K., Szymański, M., & Matławska, I. (2013). *Leonurus cardiaca* L. (Motherwort): A review of its phytochemistry and pharmacology. *Phytotherapy Research*, 27(8), 1115-1120.
 81. Debruyne, D., Albessard, F., Bigot, M. C., & Moulin, M. (1999). Comparison of the pharmacokinetics of yohimbine in humans and rats. *European Journal of Drug Metabolism and Pharmacokinetics*, 24(3), 219-224.
 82. Mahady, G. B. (2005). Black cohosh (*Actaea/Cimicifuga racemosa*): Review of the clinical data for safety and efficacy in menopausal symptoms. *Treatments in Endocrinology*, 4(3), 177-184.
 83. Kennedy, D. O., Haskell, C. F., Wesnes, K. A., & Scholey, A. B. (2004). Improved cognitive performance in human volunteers following administration of guarana (*Paullinia cupana*) extract: Comparison and interaction with *Panax ginseng*. *Pharmacology Biochemistry and Behavior*, 79(3), 401-411.
 84. Coleta, M., Campos, M. G., Cotrim, M. D., Lima, T. C., & Cunha, A. P. (2008). Assessment of luteolin (3',4',5,7-tetrahydroxyflavone) neuropharmacological activity. *Behavioural Brain Research*, 189(1), 75-82.
 85. Rigano, D., Formisano, C., Basile, A., Lavitola, A., Senatore, F., Rosselli, S., & Bruno, M. (2007). Antibacterial activity of flavonoids and phenylpropanoids from *Marrubium globosum* ssp. *libanoticum*. *Phytotherapy Research*, 21(4), 395-397.
 86. Büssing, A., Azhari, T., Ostendorp, T., Lehnert, A., & Schweizer, K. (1994). *Viscum album* L. extracts reduce sister chromatid exchanges in cultured peripheral blood mononuclear cells. *European Journal of Cancer*, 30(11), 1706-1713.

87. Wang, B. S., Wang, H., Song, Y. Y., Qi, H., Rong, Z. X., Wang, B. S., ... & Zhang, L. (2010). Effectiveness of standardized ginkgo biloba extract on cognitive symptoms of dementia with a six-month treatment: A bivariate random effect meta-analysis. *Pharmacopsychiatry*, 43(3), 86-91.
88. Wang, C., Zhang, J., Wang, F., Wang, Z., Lu, Y., & Xu, X. (2013). *Corydalis yanhusuo* rhizoma extract reduces infarct size and improves heart function during myocardial ischemia/reperfusion by inhibiting apoptosis in rats. *Phytotherapy Research*, 27(9), 1283-1289.
89. Zhang, H. Y., & Tang, X. C. (2006). Neuroprotective effects of huperzine A: New therapeutic targets for neurodegenerative disease. *Trends in Pharmacological Sciences*, 27(12), 619-625.
90. Izzo, A. A., Hoon-Kim, S., Radhakrishnan, R., & Williamson, E. M. (2016). Herb-drug interactions with St. John's Wort: Mechanisms and clinical implications. *British Journal of Pharmacology*, 174(11), 1700-1725.
91. Sarris, J., LaPorte, E., & Schweitzer, I. (2011). Kava for generalized anxiety disorder: A systematic review. *Australian & New Zealand Journal of Psychiatry*, 45(1), 27-35.
92. Berk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., ... & Malhi, G. S. (2013). Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. *Neuroscience & Biobehavioral Reviews*, 37(4), 685-704.
93. Kulkarni, S. K., & Dhir, A. (2010). An overview of curcumin in neurological disorders. *Indian Journal of Pharmaceutical Sciences*, 72(2), 149-154.
94. Panossian, A., & Wikman, G. (2010). Effects of adaptogens on the central nervous system and the molecular mechanisms associated with their stress-protective activity. *Pharmaceuticals*, 3(1), 188-224.
95. Sarris, J. (2018). Herbal medicines in the treatment of psychiatric disorders: A 10-year updated review. *Phytotherapy Research*, 32(7), 1147-1162.
96. Prasad, S., Tyagi, A. K., & Aggarwal, B. B. (2014). Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: The golden pigment from golden spice. *Cancer Research and Treatment*, 46(1), 2-18.
97. Teschke, R., Sarris, J., & Lebot, V. (2011). Kava hepatotoxicity solution: A six-point plan for new kava standardization. *Phytomedicine*, 18(2-3), 96-103.
98. Henderson, L., Yue, Q. Y., Bergquist, C., Gerden, B., & Arlett, P. (2002). St John's wort (*Hypericum perforatum*): Drug interactions and clinical outcomes. *British Journal of Clinical Pharmacology*, 54(4), 349-356.
99. Hausenblas, H. A., Saha, D., Dubyak, P. J., & Anton, S. D. (2013). Saffron (*Crocus sativus* L.) and major depressive disorder: A meta-analysis of randomized clinical trials. *Journal of Integrative Medicine*, 11(6), 377-383.
100. Barnes, J., Anderson, L. A., & Phillipson, J. D. (2007). *Herbal Medicines* (3rd ed.). Pharmaceutical Press.
101. Sarris, J., Ravindran, A., Yatham, L. N., Marx, W., Rucklidge, J. J., McIntyre, R. S., ... & Schweitzer, I. (2021). Clinician guidelines for using herbal medicines in bipolar disorder. *Bipolar Disorders*, 23(6), 612-626.
102. Amsterdam, J. D., & Panossian, A. G. (2016). *Rhodiola rosea* L. as a putative botanical antidepressant. *Phytomedicine*, 23(7), 770-783.
103. Bent, S., Padula, A., Moore, D., Patterson, M., & Mehling, W. (2006). Valerian for sleep: A systematic review and meta-analysis. *American Journal of Medicine*, 119(12), 1005-1012.
104. Stough, C., Lloyd, J., Clarke, J., Downey, L. A., Hutchison, C. W., Rodgers, T., & Nathan, P. J. (2001). The chronic effects of an extract of *Bacopa monniera* (Brahmi) on cognitive function in healthy human

- subjects. *Psychopharmacology*, 156(4), 481-484.
105. Katzenschlager, R., Evans, A., Manson, A., Patsalos, P. N., Ratnaraj, N., Watt, H., ... & Lees, A. J. (2004). *Mucuna pruriens* in Parkinson's disease: A double-blind clinical and pharmacological study. *Journal of Neurology, Neurosurgery & Psychiatry*, 75(12), 1672-1677.
 106. World Health Organization. (1999). *WHO monographs on selected medicinal plants* (Vol. 1). World Health Organization.
 107. McEwen, B. S., & Gianaros, P. J. (2011). Stress- and allostasis-induced brain plasticity. *Nature Reviews Neuroscience*, 12(7), 459-467.
 108. Miller, A. H., & Raison, C. L. (2016). The role of inflammation in depression: From evolutionary imperative to modern treatment target. *Nature Reviews Immunology*, 16(1), 22-34.
 109. Ng, Q. X., Koh, S. S. H., Chan, H. W., & Ho, C. Y. X. (2017). Clinical use of curcumin in depression: A meta-analysis. *Journal of Affective Disorders*, 227, 13-19.
 110. Sarris, J., Ravindran, A., Yatham, L. N., Marx, W., Rucklidge, J. J., McIntyre, R. S., ... & Schweitzer, I. (2021). Clinician guidelines for using herbal medicines in bipolar disorder. *Bipolar Disorders*, 23(6), 612-626.
